Form 8-K - Current report:
SEC Accession No. 0001558370-24-015622
Filing Date
2024-11-14
Accepted
2024-11-14 08:00:11
Documents
15
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avbp-20241114x8k.htm   iXBRL 8-K 42048
2 EX-99.1 avbp-20241114xex99d1.htm EX-99.1 132476
3 GRAPHIC avbp-20241114xex99d1001.jpg GRAPHIC 5560
  Complete submission text file 0001558370-24-015622.txt   319612

Data Files

Seq Description Document Type Size
4 EX-101.SCH avbp-20241114.xsd EX-101.SCH 3258
5 EX-101.LAB avbp-20241114_lab.xml EX-101.LAB 16581
6 EX-101.PRE avbp-20241114_pre.xml EX-101.PRE 10714
17 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20241114x8k_htm.xml XML 5109
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 241457279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)